Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL von Northend, Michael, Wilson, William, Osborne, Wendy, Fox, Christopher P., Davies, Andrew J., El-Sharkawi, Dima, Phillips, Elizabeth H., Sim, Hau Wui, Sadullah, Shalal, Shah, Nimish, Peng, Ying Ying, Qureshi, Iman, Addada, Juanah, Mora, Rocio Figueroa, Phillips, Neil, Kuhnl, Andrea, Davies, Elizabeth, Wrench, David, McKay, Pamela, Karpha, Indrani, Cowley, Anna, Karim, Richard, Challenor, Sarah, Singh, Vikram, Burton, Cathy, Auer, Rebecca, Williams, Chris, Cunningham, Joel, Broom, Angus, Arasaretnam, Anita, Roddie, Claire, Menne, Tobias, Townsend, William

Volltext